Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 14/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394626 | 0.91 | TNIK (0.76) | TNIKMAPTRAB9AALDH1A1NR4A1 | |
| SCHEMBL3398128 | 0.87 | TNIK (0.77) | TNIKMAPTKMT2ALMNATP53 | |
| SCHEMBL3396815 | 0.87 | TNIK (0.61) | TNIKALDH1A1KMT2A | |
| SCHEMBL13224768 | 0.87 | TNIK (0.67) | TNIKMAPTRAB9ANPC1 | |
| SCHEMBL3394883 | 0.87 | TNIK (0.62) | TNIK | |
| SCHEMBL3394909 | 0.87 | TNIK (0.77) | TNIKRAB9ANPC1 | |
| SCHEMBL3394602 | 0.86 | TNIK (0.60) | TNIKMAPTRAB9AALDH1A1LMNA | |
| SCHEMBL3398691 | 0.86 | TNIK (0.64) | TNIK | |
| SCHEMBL16699434 | 0.85 | TNIK (0.82) | TNIK | |
| SCHEMBL3394635 | 0.85 | TNIK (0.63) | TNIKMAPTLMNATP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364149-B1 | TNIK INHIBITOR AND THE USE | NAT CANCER CT (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-08-26 | — | — | US | disclosed |
| US-20100137386-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-06-03 | — | — | US | disclosed |
| US-20100137386-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-06-03 | — | — | US | disclosed |
| US-20100137386-A1 | TNIK INHIBITOR AND THE USE | YAMADA TESSHI | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216795-A1 | TNIK INHIBITOR AND THE USE | TNIK, TNNI3K, TNK1 | TNIK 1/4885LRRK2 802/4885LCK 160/4885 |
| US-20100137386-A1 | TNIK INHIBITOR AND THE USE | TNIK, TNNI3K, TNK1 | TNIK 1/4885LRRK2 1095/4885LCK 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.